Develops cancer vaccines and therapies, including CAR-T cells for ovarian cancer.
Oct 2024Revenue $210K/yrExpenses $14.0M/yr
No trendCash runway ≈ 1.9 years from Jul 2026
Figures by year
When will Anixa Biosciences be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Oct 2024, revenue was $210K and expenses $14.0M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Oct 2024 | $210K | $14.0M | −$13.8M |
| Oct 2023 | $210K | $11.2M | −$11.0M |
| Oct 2021 | $512K | $13.6M | −$13.1M |
| Oct 2019 | $250K | $12.1M | −$11.9M |
| Oct 2018 | $1.11M | $15.4M | −$14.3M |
| Oct 2017 | $363K | $6.44M | −$6.08M |
| Oct 2016 | $300K | $4.81M | −$4.51M |
| Oct 2015 | $9.26M | $10.2M | −$945K |
| Oct 2014 | $3.67M | $8.71M | −$5.04M |
| Oct 2013 | $389K | $8.31M | −$7.92M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.